This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fay, W. P. Articles by Owen, W. G. Search for Related Content PubMed PubMed Citation Articles by Fay, W. P. Articles by Owen, W. G.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:1277-1284.)
© 1996 American Heart Association, Inc.

Articles

High Concentrations of Active Plasminogen Activator Inhibitor-1 in Porcine Coronary Artery Thrombi

William P. Fay; Joseph G. Murphy; Whyte G. Owen

the Department of Internal Medicine (Cardiology), University of Michigan Medical School, Ann Arbor, and the Ann Arbor Veterans Affairs Hospital (W.F.), Division of Cardiovascular Diseases and Internal Medicine (J.M.) and the Section of Hematology Research and Department of Biochemistry and Molecular Biology (W.O.), Mayo Clinic, Rochester, Minn.

Addition of exogenous plasminogen activator inhibitor-1 (PAI-1) to fibrin clots inhibits fibrinolysis in vivo. However, it is unknown whether the localized concentrations of active PAI-1 necessary to produce this antifibrinolytic effect can be recruited to acute arterial thrombi by endogenous mechanisms. We measured PAI-1 activity and antigen in porcine coronary artery thrombi that formed in response to acute vascular injury. Mean PAI-1 activity in thrombi (n=5) was 36±5.1 µg/mL, which is >2000 times its concentration in normal porcine plasma. The presence of markedly elevated concentrations of active PAI-1 in thrombi was confirmed by an immunoactivity assay and by demonstrating formation of sodium dodecyl sulfate–stable complexes after addition of ¹²⁵I-urokinase to thrombus extracts. Comparative analysis of PAI-1 antigen by Western blotting and urokinase inhibition assay suggested that approximately one third of thrombus-associated PAI-1 was active. Histological examination of coronary thrombi revealed that they consisted predominantly of dense aggregates of platelets with interspersed islands of fibrin, which closely resemble the histological appearance of thrombi in patients with myocardial infarction and unstable angina pectoris. Washed porcine platelets prepared from peripheral blood contained sufficient PAI-1 antigen and activity to account for the concentrations observed in coronary artery thrombi. However, the specific activity of human platelet PAI-1 was lower than that of porcine platelet PAI-1 (2% versus 50% active, respectively), and human platelets inhibited in vitro fibrinolysis to a lesser extent than did porcine platelets. These results indicate that active PAI-1 accumulates in porcine coronary artery thrombi in concentrations markedly higher than those present in plasma and that PAI-1 may be an important determinant of the known resistance of platelet-rich thrombi to lysis by tissue-type plasminogen activator. These studies also underscore the importance of considering possible species differences in protein function when comparing animal models of thrombosis to acute coronary thrombosis in humans.

Key Words: myocardial infarction • thrombosis • thrombolysis • platelets

This article has been cited by other articles:

				I. B. Kovacs and J. Yamamoto Spontaneous Thrombolysis: A Forgotten Determinant of Life or Death Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 358 - 363. [Abstract] [PDF]

				D. L. Crandall, D. E. Busler, B. McHendry-Rinde, T. M. Groeling, and J. G. Kral Autocrine Regulation of Human Preadipocyte Migration by Plasminogen Activator Inhibitor-1 J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2609 - 2614. [Abstract] [Full Text]

				T. Kawasaki, M. Dewerchin, H. R. Lijnen, J. Vermylen, and M. F. Hoylaerts Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice Blood, July 1, 2000; 96(1): 153 - 160. [Abstract] [Full Text] [PDF]

				Y. Zhu, P. Carmeliet, and W. P. Fay Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance Circulation, June 15, 1999; 99(23): 3050 - 3055. [Abstract] [Full Text] [PDF]

				M. Cesari and G. P. Rossi Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1378 - 1386. [Full Text] [PDF]

				R. Christopher, S. Judge, P. Vincent, P. Higgins, and P. McKeown-Longo The amino-terminal matrix assembly domain of fibronectin stabilizes cell shape and prevents cell cycle progression J. Cell Sci., January 10, 1999; 112(19): 3225 - 3235. [Abstract] [PDF]

				P. M. Farrehi, C. K. Ozaki, P. Carmeliet, and W. P. Fay Regulation of Arterial Thrombolysis by Plasminogen Activator Inhibitor-1 in Mice Circulation, March 17, 1998; 97(10): 1002 - 1008. [Abstract] [Full Text] [PDF]

				W. P. Fay, A. C. Parker, L. R. Condrey, and A. D. Shapiro Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene Blood, July 1, 1997; 90(1): 204 - 208. [Abstract] [Full Text] [PDF]

				T. J. Podor, S. G. Shaughnessy, M. N. Blackburn, and C. B. Peterson New Insights into the Size and Stoichiometry of the Plasminogen Activator Inhibitor Type-1{middle dot}Vitronectin Complex J. Biol. Chem., August 11, 2000; 275(33): 25402 - 25410. [Abstract] [Full Text] [PDF]

				K. Okada, T. Fujita, K. Minamoto, H. Liao, Y. Naka, and D. J. Pinsky Potentiation of Endogenous Fibrinolysis and Rescue from Lung Ischemia/Reperfusion Injury in Interleukin (IL)-10-reconstituted IL-10 Null Mice J. Biol. Chem., July 7, 2000; 275(28): 21468 - 21476. [Abstract] [Full Text] [PDF]